Exactis Innovation and SOPHiA GENETICS Announce Collaboration on Multimodal Data Analytics

(US and Canada) SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced a collaboration with Exactis Innovation, based in Montreal, Quebec, who will contribute to cancer research and data-driven decision-making through SOPHiA GENETICS' multimodal real-world data offering.

Exactis Innovation is a non-profit network of hospital partners across Canada dedicated to improving cancer survivorship through the acceleration of data-driven decision-making. Exactis will join the SOPHiA DDM™ network and leverage the SOPHiA DDM™ platform to access global real-world data insights from multimodal datasets. By joining the SOPHiA DDM™ network, Exactis researchers will access to a global network of data that will provide robust, diverse insights to help support research for its Canadian population.

"Our enhanced focus on real-world data positions us as a key resource for impartial insights for both industry and public sectors. Our participation in contributing to, and learning from, the collective intelligence enabled by SOPHiA GENETICS stems from our belief that the path to superior data-driven decisions lies in overcoming borders and utilizing top-tier, ready-to-use real world data," said Kostas Trakas, PhD., CEO, Exactis Innovation.

"It is our continued goal to improve health outcomes for patients globally by equipping local health institutions with the technology needed to exercise data-driven medicine," said Jurgi Camblong, PhD., CEO and Co-founder of SOPHiA GENETICS. "As health data consumption grows and becomes increasingly complex and multifaceted, it is imperative that healthcare organizations have the ability to process data in a timely manner and receive highly accurate results. SOPHiA GENETICS and Exactis Innovation have the shared vision to improve cancer survivorship in Canada by unlocking insights from medical data and contributing to a global collective intelligence."

The collaboration will also enable Exactis to implement leading cancer testing solutions for its patient population, including MSK-ACCESS® and MSK-IMPACT® powered with SOPHiA DDM™ and HRD testing. The SOPHiA DDM™ Platform will support Exactis in its ability to increase the volume and speed of next-generation sequencing (NGS) testing and tumor profiling.

"From our modest beginnings in Montreal, our network now includes 16 cancer sites throughout Canada. Our collaboration with SOPHiA GENETICS empowers us with advanced tools, enhancing our capabilities in data-driven medicine. This partnership places Canadians at the forefront of a global initiative, leveraging real world data to elevate patient care, inform critical health decisions, and foster groundbreaking discoveries," said Gerald Batist, MD, Chief Medical Officer of Exactis Innovation and Director of the Segal Cancer Centre at the Jewish General Hospital.

Exactis leads Canada's most extensive pan-cancer research initiative, encompassing nearly 10,000 patients.